Malignant Brain Tumors

A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients with Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study This single arm trial is being conducted to establish the safety and efficacy of Gliolan-Æ (5-ALA) in patients undergoing resection of newly diagnosed or recurrent malignant gliomas. The rationale for the study is that Gliolan-Æ (5-ALA), as an adjunct to tumor resection, is safe and will provide surgeons with real-time visualization of malignant tumor.

Sponsor(s)
Mount Sinai Medical Center
Principal Investigator(s)
Dr. Jonathan Sherman
Contact Phone Number
Request Information
Address

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

3 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.